Life Length® Announces New Partnership with Cleveland HeartLab® to Offer Telomere Technology in North America

Share Article

Life Length, the world leader in telomere analysis, is pleased to add Cleveland HeartLab to their current list of partner labs from across the globe.

Life Length and Cleveland HeartLab (CHL) announce a new agreement which provides CHL access to Life Length’s proprietary Telomere Analysis Technology™ (TATTM). Life Length offers the most advanced and comprehensive telomere test on the market today, and is the only commercially available telomere test that reports the percentage of short telomeres, providing the most critical information in telomere assessment.

Dr. Jerry Shay, Vice Chairman of the Department of Cell Biology at The University of Texas Southwestern Medical Center, spoke earlier this month at Cleveland HeartLab’s 5th Annual Symposium in a talk titled “Telomere Testing: An independent Biomarker for Assessing Cardiovascular Disease.” Dr. Shay stated “An analysis of 43,000 subjects shows that telomere length may independently predict risk for heart attack and stroke. We need to follow people long before they have the first heart attack and intervene at a much earlier stage.”

Stephen J. Matlin, CEO, Life Length said, “We are delighted to add Cleveland HeartLab, a premier cardiovascular disease management company, to our current list of global lab partners. Life Length’s TAT test offers a unique biomarker since telomeres are an important predictor of biological age, which is closely related with the onset of cardiovascular disease, and is an excellent general health indicator. Through our partnership with CHL more people will now have access to this proprietary technology.”

Jake Orville, President & CEO, Cleveland HeartLab, noted, “We are pleased to partner with Life Length and offer access to their proprietary TAT test to those interested in telomere assessment. Innovation is the core of our company and in addition to our own robust research and development program, partnerships like this allow us to bring cutting-edge technology to the market.”

About Life Length
Life Length, a healthcare diagnostics company founded in 2010 as a spin-off of the prestigious Spanish National Cancer Research Center is the only company in the world able to measure telomeres individually at the chromosomal level, providing the crucial measure for cell senescence, aging and age-related diseases. Life Length provides evaluation services to pharmaceutical, biotech, nutraceutical and similar industries for drug and product R&D and clinical studies, as well as to the general public through physicians and clinics working in preventive and personalized medicine and as a biomarker of health and aging in such fields as cardiology, neurology, oncology, infertility in which telomeres have been shown to play a significant contributing role in the development of these diseases. For more information go to http://www.lifelength.com.

About Cleveland Heart Lab
Cleveland HeartLab Inc. is the premier cardiovascular disease (CVD) management company offering an array of proprietary tests which aid clinicians in identifying CVD risk and reducing cardiovascular events. In addition to its industry leading approach to inflammation testing, CHL maintains a robust research and development program focused on bringing the next generation of CVD biomarkers to market. Spun out of The Cleveland Clinic in 2009, CHL offers its testing to thousands of leading clinicians focused on health and wellness as well as corporate wellness plans through its CAP-accredited and CLIA-certified clinical laboratory. Half of all patients who suffer from heart attack have normal cholesterol at the time of heart attack. CHL believes this is because cholesterol alone does not reveal a complete CVD risk profile. CHL’s unique testing provides better identification of CVD risk allowing clinicians to deploy proper medical programs to reduce the overall risk of CVD and specifically inflammation risk within their patient populations. CHL holds over 20 issued and 30 pending global patents and has been recognized for its innovation by receiving the prestigious Nortech Innovation Award, The Ohio Venture of the Year Award and the Edison Crystal Award for Excellence. For more information about CHL visit us at http://www.clevelandheartlab.com. For more information on CVD visit http://www.knowyourrisk.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Kathy Myers

Yessica Fernández-Cruz Ledel
Life Length
(805) 906 9906
Email >
Visit website